Antimicrobial Resistance: Tackling a crisis for the health ...

← Back to document page

Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations The Review on Antimicrobial Resistance Chaired by Jim O Neill December 2014 Contents The Review 2What is Antimicrobial resistance? 3The economic cost of drug-resistant infections 6Our research findings in detail 7The secondary health effects of Antimicrobial resistance: a return to the dark age of medicine? 11Future work: already we see cause for optimism 14The Review on Antimicrobial Resistance, Chaired by Jim O Neill23The Review on Antimicrobial Resistance, Chaired by Jim O NeillThe Review The UK Prime Minister announced a Review on Antimicrobial Resistance in July, calling for ideas to bring this growing threat under control.

country irrespective of its level of income. For instance, in 15 European countries more than 10% of bloodstream Staphylococcus aureus infections are caused by methicillin-resistant strains (MRSA), with several of these countries seeing resistance rates closer to 50%.1 1.

  Country